as a Disease Tackling the Core of the Condition IntroductionBackground Global Prevalence of Obesity Tracking the Global Obesity Epidemic The Impact of Obesity Upon Individuals Obesity as a Risk Factor for a Range of Comorbid Conditions ID: 655493
Download Presentation The PPT/PDF document "The Fight Against Obesity" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
The Fight Against Obesity as a Disease: Tackling the Core of the ConditionSlide2Slide3
Introduction/BackgroundSlide4
Global Prevalence of ObesitySlide5
Tracking the Global Obesity EpidemicSlide6
The Impact of Obesity Upon IndividualsSlide7
Obesity as a Risk Factor for a Range of Comorbid Conditions[a,b]Slide8
Estimated Number of Cancer Cases (in Thousands) Attributable to Excess Body Mass Slide9
The Obesogenic EnvironmentSlide10
Fixing the Obesogenic EnvironmentSlide11
A Structured Program of Behavioral Change Is Beneficial for Weight LossSlide12
Look AHEAD Weight Loss MaintenanceSlide13
Dieting, and Energy Intake Regulation: The DilemmaSlide14
Mechanisms of Food Intake RegulationSlide15
Satiety Signaling and Inhibitory Control May Be Weaker in the Obesity-ProneSlide16
Weight Loss at End of Study vs Weight Loss at Follow-upSlide17
Weight Loss Improves Obesity-Related ComorbiditiesSlide18
Factors Driving Weight Regain or Weight Loss Maintenance after Initial Weight LossSlide19
Proportion of Patients Achieving > 5% Weight Loss at Year 1: Liraglutide, Orlistat, PlaceboSlide20
Percentage Weight Loss From Baseline for the Modified-ITT-LOCF Population and the Completer Population: Naltrexone + Bupropion vs PlaceboSlide21
SCALE: Change in Body Weight (%), Liraglutide vs PlaceboSlide22
SCALE Maintenance: Proportion of Patients Maintaining Run-In Weight Loss or Regaining ≥ 5% From Randomization to Week 56Slide23
NICE Guidelines for the Treatment of Overweight/ObesitySlide24
Weight Loss SurgerySlide25
Bariatric Surgery: Mechanisms of Action in Weight LossSlide26
Bariatric Surgery Is Associated With Sustained Weight Loss Over 15 YearsSlide27
Bariatric Surgery and T2DM Prevention or RemissionSlide28
Bariatric Surgery and the Risk of "Addiction Transfer"Slide29
ConclusionsSlide30
AbbreviationsSlide31
Abbreviations (cont)